Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,018 across all filing types
Latest filing 2018-03-23 Proxy Solicitation & In…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
UCB SA Procuration Assemblée Générale 26 avril 2018 .pdf
Proxy Solicitation & Information Statement Classification · 99% confidence The document is explicitly titled "PROCURATION POUR L'ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES DU 26 AVRIL 2018" (Proxy for the General Shareholders' Meeting of April 26, 2018). It contains instructions for shareholders on how to appoint a proxy to vote on various resolutions, including the approval of annual accounts, remuneration reports, director re-elections, and long-term incentive plans. This material is designed to solicit shareholder votes and provide necessary information ahead of the meeting, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). Although it touches upon items typically found in an Annual Report (like approving 2017 accounts), the document's primary function is soliciting proxy votes for the AGM.
2018-03-23 French
2017 jaarverslag (finaal).pdf
Annual Report Classification · 100% confidence The document is titled 'Jaarverslag 2017' (Annual Report 2017) for UCB. It contains a comprehensive overview of the company's performance, including a letter to stakeholders, strategy, personnel, R&D, financial highlights, and a detailed table of contents referencing consolidated financial statements and auditor reports. It is clearly the full annual report, not an announcement or summary. FY 2017
2018-03-23 Dutch
2103 - Bio Jean-Christophe Tellier.pdf
Board/Management Information Classification · 99% confidence The document provides a detailed biography and professional history of Jean-Christophe Tellier, the Chief Executive Officer and Chairman of the Executive Committee of UCB. It lists his roles, past positions at other companies (Ipsen, Macrogenics, Novartis), education, and personal philosophy regarding patient care and leadership. This content directly relates to the composition and leadership of the company's management team. This aligns perfectly with the definition of Board/Management Information (MANG), which covers announcements of changes or profiles of senior management.
2018-03-23 English
NBB_0019_31.12.2017_FR Final signé.pdf
Annual Report Classification · 95% confidence The document is a formal Belgian annual financial filing ('Comptes Annuels') for UCB SA, containing detailed balance sheets, identification data, and lists of directors. It represents the full annual financial reporting package rather than a summary or announcement. Given the comprehensive nature of the financial statements provided, it is classified as an Annual Report (10-K equivalent in this context). FY 2017
2018-03-23 French
Verslag van de commissaris - Jaarrekening UCB NV.pdf
Audit Report / Information Classification · 99% confidence The document is titled "Verslag van de commissaris aan de algemene vergadering van aandeelhouders over het boekjaar afgesloten op 31 december 2017" (Report of the statutory auditor to the general meeting of shareholders for the financial year ended December 31, 2017). The content explicitly details the auditor's opinion ("Oordeel zonder voorbehoud" - Unqualified Opinion) on the financial statements, discusses key audit matters, and outlines the responsibilities of the auditor according to Belgian law and International Standards on Auditing (ISA's). This structure is characteristic of a formal Audit Report or the auditor's section within the annual reporting package, but since it is specifically the *Auditor's Report* detailing the audit findings and opinion on the financial statements, it aligns best with the 'Audit Report / Information' category (AR), rather than the full 'Annual Report' (10-K) or a mere 'Report Publication Announcement' (RPA), given its substantial length and detailed content. FY 2017
2018-03-23 Dutch
Statutory Auditor's report - Accounts UCB SA.pdf
Audit Report / Information Classification · 98% confidence The document is explicitly titled "Statutory auditor's report to the general shareholders' meeting for the year ended 31 December 2017" and contains sections like "Report on the audit of the annual accounts," "Unqualified opinion," and detailed auditor responsibilities. This content is characteristic of a formal audit report accompanying the annual financial statements, rather than the full Annual Report (10-K) itself, or a mere announcement of an audit report. Given the specific focus on the audit opinion and procedures, the most appropriate classification is Audit Report / Information (AR). It is a comprehensive report detailing audit findings, not just a short announcement (RPA/RNS). FY 2017
2018-03-23 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.